Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
Wave Life Sciences (Nasdaq: WVE) announced that Paul Bolno, MD, MBA, President and CEO, will participate in a virtual fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 2:40 p.m. ET.
A live webcast will be available via the company's Investor Events page and a replay will be archived for a limited time.
Positive
- None.
Negative
- None.
News Market Reaction – WVE
On the day this news was published, WVE gained 0.07%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Select biotech peers show mixed moves: CVAC +1.97%, ELVN +0.31%, STOK +0.09%, while PGEN -1.57% and ZYME -1.90%. Momentum scanner shows only RCUS moving up 2.58% with no news, suggesting today’s setup around WVE’s conference appearance is more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 19 | Earnings call scheduled | Neutral | +0.9% | Announced date and webcast details for Q4 and full-year 2025 results. |
| Feb 02 | Regulatory strategy update | Positive | +3.8% | Regained WVE-006 rights, outlined accelerated regulatory plans and milestone potential. |
| Jan 12 | Pipeline priorities update | Positive | +0.5% | Detailed 2026 priorities for obesity candidate and RNA editing portfolio with cash runway. |
| Jan 05 | Conference presentation | Neutral | -6.0% | Notified investors of J.P. Morgan conference presentation and webcast access. |
| Dec 09 | Equity offering priced | Negative | +15.1% | Priced upsized public offering of ordinary shares and pre-funded warrants. |
Substantive pipeline and strategic updates have coincided with positive moves, while event-only announcements and financing have shown mixed or divergent reactions.
Over the last few months, Wave Life Sciences issued several notable updates. On Feb 2, 2026, it announced accelerated regulatory plans and expanded collaboration economics, with a +3.79% move. Strategic priorities for 2026 on Jan 12, 2026 were followed by a modest +0.51% reaction. By contrast, a simple conference appearance notice on Jan 5, 2026 saw a -5.96% move, and the $350M offering on Dec 9, 2025 coincided with a +15.06% gain, highlighting non-linear reactions to financing and event news.
Market Pulse Summary
This announcement centers on management’s participation in an analyst-led fireside chat at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference on February 26, 2026. Historically, Wave’s stock has reacted more to substantive pipeline, regulatory, and financing updates than to event notices alone. Shares currently trade above the 200-day MA and remain well below the 52-week high, so investors may focus on any incremental insights shared during the webcast rather than the conference appearance itself.
Key Terms
rna medical
AI-generated analysis. Not financial advice.
CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 2:40 p.m. ET.
A live webcast of the presentation can be accessed by visiting “Investor Events” on the Investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. A replay of this presentation will be archived and available on the site for a limited time following the event.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.
Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827
Investors:
James Salierno
Director, Investor Relations
+1 617-949-4043
InvestorRelations@wavelifesci.com
Media:
Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
MediaRelations@wavelifesci.com
FAQ
When will Wave Life Sciences (WVE) present at the Oppenheimer Healthcare Life Sciences Conference?
Who from Wave Life Sciences (WVE) will speak at the February 26, 2026 conference?
How can investors watch Wave Life Sciences (WVE) at the Oppenheimer conference?
Will Wave Life Sciences (WVE) provide a replay of the Oppenheimer presentation?
What topics will Wave Life Sciences (WVE) likely cover in the February 26, 2026 fireside chat?
